Terbinafine 250 mg (Tablet)
Treatment of dermatophyte fungal infections of the fingernails and toenails
Final regulatory approval
Our pipeline
Explore our products progressing toward commercial launch with their generic name, dosage form, therapy area and regulatory status.
Packaging review
Final regulatory approval
Infectious Diseases
Itraconazole USP 100 mg (Capsule)
Treatment of susceptible systemic and superficial fungal infections
Final regulatory approval
Itraconazole BP 200 mg (Tablet)
Treatment of susceptible systemic and superficial fungal infections
Final regulatory approval
Voriconazole USP 200 mg (Tablet)
Treatment of serious invasive fungal infections
Final regulatory approval
Cefuroxime 250 mg + clavulanic acid 62.5 mg (Tablet)
Oral treatment of susceptible bacterial infections
Packaging review
Cefuroxime 500 mg + clavulanic acid 125 mg (Tablet)
Oral treatment of susceptible bacterial infections
Packaging review
Cefuroxime 125 mg + clavulanic acid 31.25 mg/5 ml (Powder for suspension)
Oral treatment of susceptible bacterial infections
Packaging review
Cefixime 400 mg (Capsule)
Treatment of susceptible respiratory, urinary and throat infections
Packaging review
Ceftriaxone 1 g/vial (IV injection)
Treatment of serious susceptible bacterial infections
Packaging review
Ceftriaxone 2 g/vial (IV injection)
Treatment of serious susceptible bacterial infections
Packaging review
Meropenem 1 g/vial (IV injection)
Treatment of serious and complicated susceptible bacterial infections
Packaging review
Meropenem 500 mg/vial (IV injection)
Treatment of serious and complicated susceptible bacterial infections
Packaging review
Gastrointestinal Care
Ondansetron 8 mg (Tablet)
Prevention of chemotherapy-, radiotherapy- and surgery-related nausea and vomiting
Final regulatory approval
Ondansetron 4 mg/5 ml (Oral solution)
Prevention of chemotherapy-, radiotherapy- and surgery-related nausea and vomiting
Final regulatory approval
Tiemonium methylsulfate INN 50 mg (Tablet)
Relief of gastrointestinal, biliary and genitourinary smooth-muscle spasm
Final regulatory approval
Sodium picosulfate BP 10 mg (Tablet)
Short-term relief of constipation
Final regulatory approval
Sodium alginate BP 500 mg + sodium bicarbonate BP 267 mg + calcium carbonate BP 160 mg/10 ml (Oral suspension)
Relief of heartburn, acid indigestion and reflux symptoms
Packaging review
Omeprazole 40 mg/vial (IV injection)
Acid suppression when oral therapy is inappropriate
Packaging review
Tiemonium methylsulfate INN 5 mg/2 ml (Injection)
Relief of gastrointestinal, biliary and genitourinary smooth-muscle spasm
Packaging review
Pain & Acute Care
Tolfenamic acid BP 200 mg (Tablet)
Acute treatment of migraine attacks
Final regulatory approval
Ketorolac tromethamine USP 30 mg/ml (Injection)
Short-term management of moderately severe acute pain
Packaging review
Ketorolac tromethamine USP 60 mg/2 ml (Injection)
Short-term management of moderately severe acute pain
Packaging review
Lidocaine hydrochloride BP 1 g/100 ml (Injection)
Local or regional anaesthesia for procedures
Packaging review
Other Areas
Bilastine INN 20 mg (Tablet)
Symptom relief in allergic rhinoconjunctivitis and urticaria
Final regulatory approval
Amlodipine besylate BP 5 mg + olmesartan medoxomil USP 20 mg (Tablet)
Treatment of hypertension to lower blood pressure
Final regulatory approval
Water for injection BP 10 ml/ampoule (Injection)
Sterile solvent or diluent for injectable medicines
Packaging review
Multivitamin & multimineral preparation (Tablet)
Vitamin and mineral supplementation
Packaging review